FibroGen, Inc - Common Stock (FGEN)
0.4837
-0.0189 (-3.76%)
FibroGen Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for anemia, fibrotic diseases, and chronic kidney disease
The organization focuses on the development of novel treatments that harness the body's natural processes to promote healthy red blood cell production and reduce fibrosis, thereby addressing significant unmet medical needs. Through its cutting-edge research and clinical trials, FibroGen aims to improve patient outcomes and enhance the quality of life for individuals suffering from these serious health conditions.